Product category:
Chemicals and biochemicals
News Release from: Invitrogen | Subject: Tfi DNA Polymerase
Edited by the Laboratorytalk Editorial
Team on 14 September 2005
Polymerase is a cost-effective
alternative to Taq
DNA polymerase can be considered for use as a component in a diagnostic application if qualified by the end user, and does not carry the licensing restrictions, or costs, that Taq does
Invitrogen has introduced its Tfi DNA polymerase - a robust, cost-effective alternative to Taq PCR performance is comparable to Taq DNA polymerase in yield, specificity, fidelity, and robustness, says the company
It can be substituted for Taq DNA polymerase in virtually any application and is ideal for genomic and cDNA targets less than 4kb.
It can be considered for use as a component in a diagnostic application if qualified by the end user.
In addition, Tfi does not carry the licensing restrictions, or costs, that Taq does.
• Invitrogen: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
